KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) EPS (Basic) (2016 - 2026)

Pfizer has reported EPS (Basic) over the past 18 years, most recently at $0.48 for Q1 2026.

  • Quarterly EPS (Basic) fell 7.69% to $0.48 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.32 through Mar 2026, changed 0.0% year-over-year, with the annual reading at $1.37 for FY2025, 3.52% down from the prior year.
  • EPS (Basic) was $0.48 for Q1 2026 at Pfizer, up from -$0.29 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $1.77 in Q3 2022 and troughed at -$0.59 in Q4 2023.
  • The 5-year median for EPS (Basic) is $0.52 (2025), against an average of $0.55.
  • Year-over-year, EPS (Basic) tumbled 127.27% in 2023 and then surged 5000.0% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at $1.54 in 2022, then plummeted by 138.31% to -$0.59 in 2023, then skyrocketed by 233.9% to $0.79 in 2024, then plummeted by 136.71% to -$0.29 in 2025, then surged by 265.52% to $0.48 in 2026.
  • Per Business Quant, the three most recent readings for PFE's EPS (Basic) are $0.48 (Q1 2026), -$0.29 (Q4 2025), and $0.62 (Q3 2025).